BCG Vaccine and Its Derivatives: Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy

Evan M. Hersh, Jordan U. Gutterman, Giora M. Mavligit, Richard C. Reed, Stephen P Richman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.

Original languageEnglish (US)
Pages (from-to)646-650
Number of pages5
JournalJAMA - Journal of the American Medical Association
Volume235
Issue number6
DOIs
StatePublished - Feb 9 1976
Externally publishedYes

Fingerprint

BCG Vaccine
Immunotherapy
Neoplasms
Head and Neck Neoplasms
Clinical Trials
Poisons
Acute Myeloid Leukemia
Colonic Neoplasms
Melanoma
Lymphoma
Appointments and Schedules
Radiotherapy
Macrophages
Antigens
Drug Therapy
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

BCG Vaccine and Its Derivatives : Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy. / Hersh, Evan M.; Gutterman, Jordan U.; Mavligit, Giora M.; Reed, Richard C.; Richman, Stephen P.

In: JAMA - Journal of the American Medical Association, Vol. 235, No. 6, 09.02.1976, p. 646-650.

Research output: Contribution to journalArticle

Hersh, Evan M. ; Gutterman, Jordan U. ; Mavligit, Giora M. ; Reed, Richard C. ; Richman, Stephen P. / BCG Vaccine and Its Derivatives : Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy. In: JAMA - Journal of the American Medical Association. 1976 ; Vol. 235, No. 6. pp. 646-650.
@article{d7911068421646899a3a8adba091a637,
title = "BCG Vaccine and Its Derivatives: Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy",
abstract = "BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.",
author = "Hersh, {Evan M.} and Gutterman, {Jordan U.} and Mavligit, {Giora M.} and Reed, {Richard C.} and Richman, {Stephen P}",
year = "1976",
month = "2",
day = "9",
doi = "10.1001/jama.1976.03260320052031",
language = "English (US)",
volume = "235",
pages = "646--650",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - BCG Vaccine and Its Derivatives

T2 - Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy

AU - Hersh, Evan M.

AU - Gutterman, Jordan U.

AU - Mavligit, Giora M.

AU - Reed, Richard C.

AU - Richman, Stephen P

PY - 1976/2/9

Y1 - 1976/2/9

N2 - BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.

AB - BCG vaccine is undergoing extensive clinical trials for cancer immunotherapy. These studies are based on its immunopotentiating and macrophage-activating properties. Efficacy of BCG vaccine probably depends on strain, proportion of viable organisms, absence of free soluble antigens, dose, route, and schedule of administration. BCG vaccine is most efficacious when administered in conjunction with or following intensive cytoreductive maneuvers such as surgery, radiotherapy, or chemotherapy. BCG vaccine has shown beneficial activity in acute myelogenous leukemia, malignant melanoma, colon cancer, lymphoma, head and neck cancer, and other tumors. Since BCG vaccine has toxic side effects, and since less than optimal preparations can be detrimental in terms of tumor control, progress in the development of BCG vaccine immunotherapy must be based on sound clinical trials, careful clinical and immunological evaluation of treated subjects, and continuing research on basic and applied aspects of its immunological and other biological activities.

UR - http://www.scopus.com/inward/record.url?scp=0017228126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017228126&partnerID=8YFLogxK

U2 - 10.1001/jama.1976.03260320052031

DO - 10.1001/jama.1976.03260320052031

M3 - Article

AN - SCOPUS:0017228126

VL - 235

SP - 646

EP - 650

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 6

ER -